Product
Anti-CD19 Autologous CAR-T Cell Infusion
1 clinical trial
3 indications
Indication
B-Cell LeukemiaIndication
B-cell lymphomaIndication
B-cell TumorsClinical trial
An Open Label, Single-site, Dose-escalation Study Aiming to Evaluate the Efficacy and Safety of Anti-CD19 CAR-T Manufactured by OlyCAR Platform(OlyCAR-019) in the Treatment of Relapsed/ Refractory(r/r) B-Cell MalignanciesStatus: Recruiting, Estimated PCD: 2024-06-30